HIV envelope antigen valency on peptide nanofibers modulates antibody magnitude and binding breadth.
Ontology highlight
ABSTRACT: A major challenge in developing an effective vaccine against HIV-1 is the genetic diversity of its viral envelope. Because of the broad range of sequences exhibited by HIV-1 strains, protective antibodies must be able to bind and neutralize a widely mutated viral envelope protein. No vaccine has yet been designed which induces broadly neutralizing or protective immune responses against HIV in humans. Nanomaterial-based vaccines have shown the ability to generate antibody and cellular immune responses of increased breadth and neutralization potency. Thus, we have developed supramolecular nanofiber-based immunogens bearing the HIV gp120 envelope glycoprotein. These immunogens generated antibody responses that had increased magnitude and binding breadth compared to soluble gp120. By varying g
SUBMITTER: Fries CN
PROVIDER: S-EPMC8280189 | biostudies-literature | 2021 Jul
REPOSITORIES: biostudies-literature
ACCESS DATA